Case Report: Renal Cell Carcinoma of First Kidney Allograft in Transplanted Recipient for Second Time

Abstract

The uses of immunosuppressive therapy to preserve the new allograft function can significantly increase the incidence of malignancies in transplanted recipients compared with that of general population. The ability to identify and prevent solid organ tumours in the transplant patients, particularly early stages carcinomas depends on regular screening examinations and strict adherence to prophylactic measures. Screening of the patient and donor prior to transplant can help to detect any underlying pre-existing malignancy. Identification of tumor in renal allograft are usually accidental following ultrasonography, CT scan or MRI imaging, so special attention is essential during any imaging examination of renal allograft to detect an early probable tumours.

We hereby, present a case record of 51 years old male who had his first kidney transplant in 1987 on the right side from living unrelated donor; he had approached ESRD in 2006 and underwent his second renal transplantation in June 2006 on the left side from living unrelated donor. Though he had stable kidney function, he started to have intermittent haematuria with lump at right lower loin. Allograft sonography had revealed a big mass in the first right transplanted kidney. CT scan with contrast demonstrated a large lobulated enhancing mass arising from the iliac fossa of first transplanted kidney with local, right common iliac vein metastasis and lungs metastasis. Due to above finding patient underwent right allograft nephrectomy.

Keywords: Immunosuppression; Kidney transplantation, Renal cell carcinoma

Introduction

A post-transplant tumours are variable with large diverse in incidences and prognosis. Malignancies are considered to be the second most common cause of mortality among transplanted recipients after cardiovascular diseases [1]. In patients with the renal transplant; malignancies of the urinary tract is the second most common following skin tumours. The most affected organs are prostate, kidneys, bladder and testes [2]. Diagnosis of tumours in renal allograft are usually accidental following ultrasonography, CT scan or MRI imaging, so special attention is essential during imaging examination of renal allograft to detect any probable tumor at early stage [3].

Case report

A 51 years old male, with history of end stage renal disease due to chronic glomerulonephritis, had undergone his first kidney transplantation in 1987 at right side from living unrelated donor. He was maintained on three immunosuppressant’s; prednisolone, cyclosporine and azathioprine. He was doing well with baseline creatinine of 1.2 mg /dl to 1.5mg/dl, subsequently his serum creatinine start rising gradually till he approached End Stage Renal Diseases (ESRD) by 2006. A second renal transplantation was done in June 2006 at the left side from living unrelated donor; thereafter he was maintained on steroid, cyclosporine and Mycophenolate with baseline creatinine of 1.2mgdl to1.3mgdl, he had stable allograft function. In 2013 he developed new onset diabetes after transplant (NODAT). Due to urethral stricture he underwent several internal urethrotomy procedures in the past few years.

Over a few months, he was complaining of intermittent haematuria with a bulge noticed at the right lower loin. Ultrasound was done in April 2015; and revealed a big mass in the right old transplant kidney (see image 1A, 1B). CT scan with contrast demonstrated a large lobulated enhancing mass arising from the iliac fossa of first transplanted kidney with local, right common iliac vein metastasis and lungs metastasis. Due to above finding patient underwent right allograft nephrectomy.

Keywords: Immunosuppression; Kidney transplantation, Renal cell carcinoma

Abbreviations: ESRD: End Stage Renal Diseases; NODAT: New Onset Diabetes After Transplant; RCC: Renal Cell Carcinoma; ARCD: Acquired Renal Cystic Disease; PCR: Polymerase Chain Reaction; PSA: Prostate Specific Antigen

Volume 3 Issue 7 - 2016

Hind H AlNour*, Fakhriya J Alalawi, Amna Khalifa and Salam Alhasani

Department of Nephrology and Urology, Dubai hospital, UAE

*Corresponding author: Hind H AlNour, Department of Nephrology, Dubai Health Authority, Dubai, UAE, Tel: 0097150-6746201; Email: hnahour@yahoo.com

Received: October 29, 2016 | Published: December 30, 2016
Discussion

Kidney transplant recipients are at higher risk of developing carcinoma of the native kidneys especially if they were on long dialysis period [4,5], the exact cause behind these remains unclear; it was postulated that different factors like developing tubular hyperplasia during the duration of advanced kidney failure can be attributed. Alternative cause is cyst formation with likely chance of malignant transformation [4,6]. Other factors like genetic factors, chronic viral infections, cigarette smoking, radiation, longer graft survival, older donor as well as recipient, African Americans and introduction of more potent immunosuppression were all encountered too [6,7]. The occurrence of graft rejection in the first post-transplant year can increase the incidence of secondary neoplasm; possibly due to escalation of immunosuppressive level required to treat the rejection episode [4,6].

Role of immunosuppression in the development of post-transplant malignancies

The increased risk of post-transplant malignancy is consistent with the increased levels of immunosuppressive therapy. Studies had demonstrated that usage of cyclosporine as well as tacrolimus, may promote malignancy following renal transplantation through an increased production of transforming growth factor beta [4]. The use of azathioprine has been associated with post-transplant malignancy, particularly an increased risk of cutaneous squamous cell carcinomas [4]. On the other hand, there is convincing proof that avoiding CNIs and use of mTOR-inhibitors (such as Sirolimus and Everolimus) can convey advantages as for the advancement of malignancy [4,8-12], this was illustrated on several studies, e.g. patients in CONVERT study who were converted to sirolimus; had a reduction in the rate of malignancies compared to those who remained on CNI at 12 and 24 months (3% versus 10%) [9,13-15]. mTOR-I has cytostatic effect and no cytotoxic activities, so the clinical effect is stabilization of the tumor cells rather than progression.

The mechanism by which m-TOR-I can induce this anti-tumor activity is related to up-regulation of adhesion molecules and to a change to less aggressive phenotype of tumoral cells, as shown by Luan et al. [16] who demonstrated that Sirolimus can modify tumor cells from aggressive phenotypes like spindle- or dome-shaped cells to a less aggressive cuboidal form in renal cell carcinoma. Additionally, m-TOR-I can block growth-factor-stimulating cell multiplication of haematopoietic and non-haematopoietic cells (e.g. CNS, hepatocytes, renal, melanocytic, osteoblastic, myogenic, fibroblasts and endothelial cells) by forming a complex with the intracellular immunophilins FKBP-12. In the pre-clinical models; m-TOR-I had demonstrated growth inhibition of tumoral cells by expanding expression of E-cadherin and p27-kip1, additionally it diminish cyclin-d1 expression, causing arrest in cellular progression from G1 to S-phase [13,14,17-19]. Conversely, mTOR-I are associated with an increased risk of mortality secondary to cardiovascular disease and infections.

Renal cell carcinoma of the grafted kidney

Renal cell carcinoma (RCC) is the most frequent malignant kidney tumor. Its incidence in transplanted patients is slightly higher than in the general population (4.8 vs. 2.3%). Most of these tumours are situated in the native kidneys, while less than 10% is located in the allograft [6,20,21]. Renal cell carcinoma in kidney transplant recipients can originate either from the donor, or as a pre-existent tumor in the recipient before transplantation, or as a de-novo malignancy that occurs post-transplant in the native kidney.
or in allograft [20,21]. Generally, they have less aggressive nature in transplanted patients, independently of their location, except for the papillary tumor RCC, in which an increased aggressiveness is reported. Papillary renal cell carcinoma represents 5-15% of overall kidney neoplasm [22,23]. Moreover, papillary tumours are more frequent in the transplanted population than in the general population and are usually associated with acquired renal cystic disease (ARCD) of the native kidneys rather than allograft [20].

Absence of graft innervation had provoked those patients to be asymptomatic at the time of diagnosis, and usually they are discovered incidentally when routine imaging is carried out during the period follow-up. Therefore it is recommended to monitor post-transplant recipients for microscopic or gross haematuria by urine analysis every three to six-months; if this is positive then urine culture has to be done in addition to urine cytology, furthermore urine polymerase chain reaction (PCR) for BK polyomavirus, prostate specific antigen (PSA) in male patients, and ultrasound of the native kidney and transplanted kidney with the bladder should be done [4,20]. Additionally, it has been advised to perform routine ultrasonography of the transplanted kidney lifelong on yearly basis [3]. This technique allows initial diagnosis to be made, whereas the images can be confirmed by CT or MRI thereafter [20].

Treatment

Radical nephrectomy and radiotherapy can cure patients with renal cell carcinoma. Radical nephrectomy were justified by a large lesion, a low functioning graft, two or more lesions, locally invasive tumor or diffuse graft infiltration on radiological studies [2]. In the recent years, partial nephrectomy (Nephron sparing surgery) has been performed widely with great success. It is usually performed when the tumours are clinically localized and the size of the tumor is 6cm or less (Stage 1A and possibly stage 1B) [2,21,2,4,25].

Percutaneous radiofrequency or cryoablation therapy is well-established treatment for small and exophytic lesions since it is less invasive and has a low mortality rate besides it avoids renal ischemia associated with vascular clamping which is occasionally necessary [23]. Minimization or withdrawal of Calcineurin inhibitors and replace it with mTOR inhibitor (Sirolimus or Everolimus) is recommended [23]. However, some authors prefer to maintain similar immunosuppressive schemes without modifications, as this will lead to decrease in the rejection risk and hence no clear correlation between immunosuppression and tumours in some reported literatures [26].

Conclusions and recommendations

i. The ability to identify and prevent solid organ tumours in the transplant recipients, especially early stage carcinomas depends on regular screening examinations and strict adherence to prophylactic measures.

ii. Cautious screening of the patient and donor prior to transplantation can help in detecting any underlying pre-existing malignancy [3].

iii. Immunologic human leukocyte antigen typing and (DNA) genetic analysis should be done on each tumor specimen when possible, to detect the recipient or donor origin of the malignancy [3,4,23,27-29].

iv. Renal cell carcinoma in post-transplant recipients is commonly to occur in the native kidneys rather than allograft kidney.

v. Renal allograft sonography should be done annually for life [2].

vi. When the tumor is symptomatic, it often has a poorer prognosis [23].

vii. If the tumor is small and localized; it can be treated with conservative management like radio frequency ablation or partial nephrectomy.

viii. Total transplant nephrectomy can give a durable cure but it will return patient to chronic dialysis.

References

1. Véghó G, Toronyi É, Hajdu M, Píros L, Görgő D, et al. (2011) Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant Proc 43(4):1261-1263.

2. Ianhez LE, Lucon M, Nahas WC, SABBAGA R, Saldana JA, et al. (2007) Renal Cell Carcinoma in Renal Transplant Patients. Urology 69(3): 462-464.

3. Leonardou P, Semelka RC, Mastropasqua M, Kamematsu M, Woosley JT (2003) Renal cell carcinoma in a transplanted kidney: MR imaging findings. Magn Reson Imaging 21(6): 691-693.

4. Brennan DC, Rodeheffer RJ, Ambinder RF, Murphy B, Lam AQ, et al. (2015) Development of malignancy following solid organ transplantation.

5. Birkeland SA, Låkkegaard H, Storm HH (2000) Cancer risk in patients on dialysis and after renal transplantation, Research letters. THE LANCET 355(9218): 1886-1887.

6. Hurst FP, Jindal RM, Graham LJ, Fatta EM, Ekster EA, et al. (2010) Incidence, Predictors, Costs, and Outcome of Renal Cell Carcinoma After Transplantation: USRDS Experience. Transplantation 90(8): 898-904.

7. Chapman JR, Webster AC, Wong G (2013) Cancer in the transplant recipient. Cold Spring Harb Perspect Med 3(7):a015677.

8. Russ GR (2013) Optimising the use of mTOR inhibitors in renal Transplantation. Transplantation Res 2(Suppl 1): 54.

9. Flavio Vincenti (2012) CNI Sparing With mTOR Inhibitors in Kidney Transplantation. Medscape Education Transplantation.

10. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, et al. (2001) Sirolimus Allows Early Cyclosporine Withdrawal In Renal Transplantation Resulting In Improved Renal Function And Lower Blood Pressure. Transplantation 72(5): 777-786.

11. Oberbauer R, Segolini G, Campistol JM, Kreis H, Mota A, et al. (2005) Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 18(1): 22-28.
Case Report: Renal Cell Carcinoma of First Kidney Allograft in Transplanted Recipient for Second Time

12. Piselli P, Busnach G, Gitterio F, Richiardi L, Cimaglia C, et al. (2008) Kidney transplant and cancer risk: an epidemiological study in Northern and Central Italy. Epidemiol Prev 32(4-5): 205-211.

13. Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, et al. (2007) Sirolimus in renal transplantation. Nephrol Dial Transplant 22(Suppl 8): v861-v865.

14. Patel SJ, Dawson KL, Knight RJ, Abdellati A, Achkar K, et al. (2011) The Role of mTOR Inhibition in Renal Transplant Immune Suppression. Dialysis & Transplantation 40(1).

15. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, et al. (2009) Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. Transplantation 87(2): 233-242.

16. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M (2002) Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73(10): 1565-1572.

17. Gianluigi Zaza, Paola Tomei, Paolo Ria, Simona Granata, Luigino Boschiero, et al. (2013) Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors. Clinical and Developmental Immunology Article ID 403280.

18. Nashan B (2004) Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. Transpl Int 17(6): 179-285.

19. Nguyen C, Shapiro R (2014) New immunosuppressive agents in pediatric transplantation. Clinics (Sao Paulo) 69(S1): 8-16.

20. González-López R, Bueno-Serrano G, Mayor-De Castro J, Vázquez-Escuderos JJ, Díez-Nicolás V, et al. (2009) Clinical presentation of renal cell carcinoma in renal transplant. Arch Esp Urol 62(3): 207-213.

21. Penn I (1995) Primary kidney tumors before and after transplantation. Transplantation 59(4): 480-485.

22. Tsui KH, van Ophoven A, Shvarts O, Beldegrun A (1999) Nephron-Sparing Surgery for Renal Cell Carcinoma. Rev Urol 1(4): 216-225.

23. Tillou X, Guleryuz K, Collon S, Doerfler A (2016) Renal cell carcinoma in functional renal graft: Toward ablative treatments. Transplant Rev (Orlando) 30(1): 20-26.

24. Ghafari A (2007) Transplantation of a Kidney with a Renal Cell Carcinoma after Living Donation: a Case Report. Transplant Proc 39(5): 1660-1661.

25. Siebels M, Theodorakis J, Liedl B, Schnee E, Hofstetter A (2000) Large de novo renal cell carcinoma in a 10-year-old transplanted kidney: Successful Organ-Preserving Therapy. Transplantation 69(4): 677-679.

26. Moudoni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, et al. (2006) Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int 98(2): 298-302.

27. Cornelis F, Buyx X, André M, Owen R, Bouffard-Vercelli J, et al. (2011) De Novo Renal Tumors Arising in Kidney Transplants: Midterm Outcome after Percutaneous Thermal Ablation. Radiology 260(3): 900-907.

28. Kapoor A (2008) Malignancy in Kidney Transplant Recipients. Drugs 68(1): 11-19.

29. Rouprêt M, Peraldi MN, Thaunat O, Chétien Y, Thiounn N, et al. (2004) Renal cell carcinoma of the grafted kidney: how to improve screening and graft tracking. Transplantation 77(1): 146-148.